Seeking Alpha

Valeant 2014 guidance in line with the Street

  • Valeant Pharmaceuticals (VRX +2.3%) forecasts 2014 adjusted EPS of $8.25-8.75, in line with consensus of $8.71.
  • Revenues are pegged at $8.2-8.6B vs $8.28B.
  • Expects growth across all its business units.
  • Q4 EPS seen at $2.05-2.10 and revenue at $2B, unchanged from prior guidance.
  • Valeant's plans for 2014 include: achieving annual run-rate synergies of over $900M from the acquisition of Bausch + Lomb; closing at least one significant deal; launching several products; and cutting its leverage ratio to below 4x adjusted pro forma EBITDA. (Presentation)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector